Regulation of Cancer Immune Checkpoints

Molecular and Cellular Mechanisms and Therapy

  • Jie Xu

Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 1248)

Table of contents

  1. Front Matter
    Pages i-x
  2. Jie Liu, Jie Xu
    Pages 1-6
  3. Samya Van Coillie, Bartosz Wiernicki, Jie Xu
    Pages 7-32
  4. Luoyan Ai, Antao Xu, Jie Xu
    Pages 33-59
  5. Hubing Shi, Jiang Lan, Jiqiao Yang
    Pages 83-117
  6. Shan Sun, Feng Wang
    Pages 119-141
  7. Wenhua Li, Jingbo Qie, Yao Zhang, Jinjia Chang
    Pages 167-200
  8. Yaping Zhang, Junke Zheng
    Pages 201-226
  9. Shuai Ding, Siqi Li, Shujie Zhang, Yan Li
    Pages 227-250
  10. Jean-Philippe Brosseau
    Pages 251-263
  11. Chushu Li, Bingqing Xia, Sheng Wang, Jie Xu
    Pages 265-294
  12. Huanbin Wang, Xue Han, Jie Xu
    Pages 325-346
  13. Yiting Wang, Ping Wang, Jie Xu
    Pages 347-398
  14. Yiting Wang, Haojie Lu, Caiyun Fang, Jie Xu
    Pages 399-424
  15. Haojie Lu, Caiyun Fang
    Pages 425-430
  16. Shouyan Deng, Xiaolin Zhou, Jie Xu
    Pages 431-453
  17. Ye Hu, Rui Zhang, Gang Chen
    Pages 455-483
  18. Xiao-Dong Su, Yao Shuai
    Pages 485-530
  19. Yunsheng Yuan
    Pages 531-546
  20. Yongxin Han, Li Zhu, Wei Wu, Hui Zhang, Wei Hu, Liguang Dai et al.
    Pages 547-618
  21. Jilin Wang, Teddy Yang, Jie Xu
    Pages 619-649
  22. Jie Xu, Mingyao Liu
    Pages 651-653

About this book


This book systematically reviews the most important findings on cancer immune checkpoints, sharing essential insights into this rapidly evolving yet largely unexplored research topic. The past decade has seen major advances in cancer immune checkpoint therapy, which has demonstrated impressive clinical benefits. The family of checkpoints for mediating cancer immune evasion now includes CTLA-4, PD-1/PD-L1, CD27/CD70, FGL-1/LAG-3, Siglec-15, VISTA (PD-1L)/VSIG3, CD47/SIRPA, APOE/LILRB4, TIGIT, and many others. Despite these strides, most patients do not show lasting remission, and some cancers have been completely resistant to the therapy. The potentially lethal adverse effects of checkpoint blockade represent another major challenge, the mechanisms of which remain poorly understood. Compared to the cancer signaling pathways, such as p53 and Ras, mechanistic studies on immune checkpoint pathways are still in their infancy.

To improve the responses to checkpoint blockade therapy and limit the adverse effects, it is essential to understand the molecular regulation of checkpoint molecules in both malignant and healthy cells/tissues. This book begins with an introduction to immune checkpoint therapy and its challenges, and subsequently describes the regulation of checkpoints at different levels. In closing, it discusses recent therapeutic developments based on mechanistic findings, and outlines goals for future translational studies. The book offers a valuable resource for researchers in the cancer immunotherapy field, helping to form a roadmap for checkpoint regulation and develop safer and more effective immunotherapies.


Cancer Immune checkpoints Genetic regulation Transcriptional regulation Translational regulation Posttranslational modification Intracellular and extracellular trafficking Mechanism guided therapeutics

Editors and affiliations

  • Jie Xu
    • 1
  1. 1.Institutes of Biomedical Sciences, Zhongshan-Xuhui HospitalFudan UniversityShanghaiChina

Bibliographic information

  • DOI
  • Copyright Information Springer Nature Singapore Pte Ltd. 2020
  • Publisher Name Springer, Singapore
  • eBook Packages Biomedical and Life Sciences
  • Print ISBN 978-981-15-3265-8
  • Online ISBN 978-981-15-3266-5
  • Series Print ISSN 0065-2598
  • Series Online ISSN 2214-8019
  • Buy this book on publisher's site